Relmada Therapeutics to Present at Future Leaders in the Biotech Industry Conference

Description

Company Presentation on March 20, 2015 at 3:00 PM Eastern Time.

NEW YORK, March 12, 2015 /PRNewswire/ — Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced that the Company's management will present at the 22nd Annual Future Leaders in the Biotech Industry Conference on Friday, March 20th at the Millennium Broadway Hotel & Conference Center in New York.

Relmada Therapeutics Corporate Logo

Sergio Traversa, CEO of Relmada Therapeutics, will present at 4:00 p.m. ET in Room 402/403.

Members of the investment community who are interested in meeting with Relmada's management team during the conference event should contact Christine Silverstein, director of investor relations at Relmada Therapeutics, at (212) 702-7167 or csilverstein@relmada.com.

A live webcast of Relmada's presentation will be available through the Company's website at www.relmada.com. Please register at least 10 minutes prior to the start of the presentation to ensure timely access. The webcast and presentation will also be archived on the website for 90 days after the conference.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of pain. The Company has a diversified portfolio of four lead products at various stages of development including d-Methadone, its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; MepiGel, its orphan drug designated topical formulation of the local anesthetic mepivacaine; BuTab, its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER, its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. The Company's product development efforts are guided by the internationally recognized scientific expertise of its research team. The Company's approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs. For more information, please visit Relmada's website at: www.relmada.com.

Forward-Looking Statements

This news release contains “forward-looking statements.” These statements are based on management’s current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact

Investor Contact:
Michael Becker, SVP of Finance and Corporate Development
Relmada Therapeutics Inc.
Tel: 212-702-7169
mbecker@relmada.com

Media Contact:
Maura McBride
Berry & Company Public Relations
Tel: 212-253-8881
mmcbride@berrypr.com

Logo – https://photos.prnewswire.com/prnh/20150113/168770LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/relmada-therapeutics-to-present-at-future-leaders-in-the-biotech-industry-conference-300049420.html

SOURCE Relmada Therapeutics, Inc.

Released March 12, 2015

Date Created
2015/03/12